Jun Chen1, Shu-Lan Huang, Tao Li, Xi-Lan Chen. 1. Department of Radiology, Renmin Hospital of Wuhan University, 238 Jiefang Road, Hubei Province, Wuhan 430060, People's Republic of China. lily_chenjun82@yahoo.com.cn
Abstract
INTRODUCTION: Assessment of brain tumor proliferative potential provides important prognostic information that supplements standard histopathologic grading. Proton magnetic resonance spectroscopy ((1)H-MRS) gives completely different information, relating to cell membrane proliferation, neuronal damage, energy metabolism and necrotic transformation of brain or tumor tissues. The aim of this study was to investigate the relationship between (1)H-MRS and tumor proliferative potential in astrocytomas. METHODS: We studied 34 patients with histologically verified astrocytomas using the (1)H-MRS protocol following routine MRI preoperatively. The tumor in 26 of these patients was classified as grade I/II (low grade), and the tumor in the remaining patients as grade III/IV (high grade) according to the World Health Organization classification criteria of nervous system tumors (2000). The tumor in 21 patients was homogeneous astrocytoma, and of these 17 were classified as low grade and 4 as high grade. Expression of proliferating cell nuclear antigen (PCNA) was determined immunohistochemically using streptavidin-biotin-peroxidase complex (SP) staining. RESULTS: The ratios of choline (Cho) to N-acetylaspartate (NAA) and Cho to creatine (Cr) in those with high-grade astrocytomas (n=4) were significantly higher than in those with low-grade astrocytomas (n=17) (t=2.899, P=0.009; t=3.96, P=0.001, respectively), and were found to be significantly correlated with the expression of PCNA in 21 patients with homogeneous astrocytomas (r=0.455, P=0.038; r=0.633, P=0.002, respectively). CONCLUSIONS: We conclude that (1)H-MRS may be a valuable method for predicting preoperatively the degree of malignancy of homogeneous astrocytomas by enabling the calculation of the Cho/NAA and Cho/Cr ratios in vivo, and indirect evaluation of the tumor proliferative potential and prognosis, which are not available using conventional magnetic resonance imaging (MRI).
INTRODUCTION: Assessment of brain tumor proliferative potential provides important prognostic information that supplements standard histopathologic grading. Proton magnetic resonance spectroscopy ((1)H-MRS) gives completely different information, relating to cell membrane proliferation, neuronal damage, energy metabolism and necrotic transformation of brain or tumor tissues. The aim of this study was to investigate the relationship between (1)H-MRS and tumor proliferative potential in astrocytomas. METHODS: We studied 34 patients with histologically verified astrocytomas using the (1)H-MRS protocol following routine MRI preoperatively. The tumor in 26 of these patients was classified as grade I/II (low grade), and the tumor in the remaining patients as grade III/IV (high grade) according to the World Health Organization classification criteria of nervous system tumors (2000). The tumor in 21 patients was homogeneous astrocytoma, and of these 17 were classified as low grade and 4 as high grade. Expression of proliferating cell nuclear antigen (PCNA) was determined immunohistochemically using streptavidin-biotin-peroxidase complex (SP) staining. RESULTS: The ratios of choline (Cho) to N-acetylaspartate (NAA) and Cho to creatine (Cr) in those with high-grade astrocytomas (n=4) were significantly higher than in those with low-grade astrocytomas (n=17) (t=2.899, P=0.009; t=3.96, P=0.001, respectively), and were found to be significantly correlated with the expression of PCNA in 21 patients with homogeneous astrocytomas (r=0.455, P=0.038; r=0.633, P=0.002, respectively). CONCLUSIONS: We conclude that (1)H-MRS may be a valuable method for predicting preoperatively the degree of malignancy of homogeneous astrocytomas by enabling the calculation of the Cho/NAA and Cho/Cr ratios in vivo, and indirect evaluation of the tumor proliferative potential and prognosis, which are not available using conventional magnetic resonance imaging (MRI).
Authors: P R Luyten; A J Marien; W Heindel; P H van Gerwen; K Herholz; J A den Hollander; G Friedmann; W D Heiss Journal: Radiology Date: 1990-09 Impact factor: 11.105
Authors: Reinhold Nafe; Sebastian Herminghaus; Ulrich Pilatus; Elke Hattingen; Gerhard Marquardt; Wolfgang Schlote; Heinrich Lanfermann; Friedhelm Zanella Journal: Neuropathology Date: 2004-09 Impact factor: 1.906
Authors: F Cendes; F Leproux; D Melanson; R Ethier; A Evans; T Peters; F Andermann Journal: J Comput Assist Tomogr Date: 1993 Mar-Apr Impact factor: 1.826
Authors: D Yang; Y Korogi; T Sugahara; M Kitajima; Y Shigematsu; L Liang; Y Ushio; M Takahashi Journal: Neuroradiology Date: 2002-06-29 Impact factor: 2.804
Authors: John Kurhanewicz; Daniel B Vigneron; Kevin Brindle; Eduard Y Chekmenev; Arnaud Comment; Charles H Cunningham; Ralph J Deberardinis; Gary G Green; Martin O Leach; Sunder S Rajan; Rahim R Rizi; Brian D Ross; Warren S Warren; Craig R Malloy Journal: Neoplasia Date: 2011-02 Impact factor: 5.715